Uncategorized
calendar_month Nov 16, 2026

Inhibrx Biosciences Analyst Cuts Price Target Despite Data Catalysts In 2027

Although Inhibrx Biosciences Inc (NASDAQ:INBX) reported a wider net loss for the third quarter than was previously estimated, the miss was mainly due to higher-than-anticipated other expenses, according to HC Wainwright.

The Inhibrx Biosciences Analyst: Analyst Robert Burns maintained a Buy rating but lowered the price target from $245 to $220.

The Inhibrx Biosciences Thesis: The company reported a net loss of $2.46 per share, wider than the estimated $2.14 per share, Burns said in the note.

Check out other analyst stock ratings.

He pointed out that Inhibrx Biosciences posted:

  • R&D expenses of $26.0 million compared to the estimate of $26.1 million
  • SG&A expenses of $7.8 million, versus the estimate of $7.7 million

The analyst projected a 2026 net loss of $9.22 per share, significantly worse than the prior estimate of a net loss of $8.93 per share.

Inhibrx ended the third quarter with cash and cash equivalents of around $199.5 million, which gives the company balance sheet strength that could provide “an operational runway” into the second quarter of 2028 and support multiple key data catalysts that represent “meaningful value inflection points,” Burns wrote.

He noted the following upcoming data catalysts:

  • Potential FDA approval for ozekibart by April 14, 2027 in patients with metastatic or unresectable conventional chondrosarcoma
  • Initial readout from the Phase 2 expansion trial of ordastobart (INBRX-106) in HPV+ HNSCC in mid-2027
  • Initial results from its Phase 1/2 study of ordastobart in the perioperative NSCLC setting in mid-2027

The company will execute an equity raise in the third quarter of 2027.

INBX Price Action: Shares of Inhibrx Biosciences had declined by 4.54% to $79.52 at the time of publication on Monday.

Image: Shutterstock